Citigroup’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
Other funds holding GRCE
OM
Citigroup's GRCE Position: Q3 2026 in Review
Citigroup opened a new position in Grace Therapeutics (GRCE) in Q3 2026: 35,481 shares worth $76.3K. The stake represents ﹤0.01% of the portfolio and ranks #4561 among its holdings. This is a return to the name: Citigroup previously reported a position in GRCE as recently as Q3 2025.
Citigroup first reported a position in GRCE in Q1 2014 and has held it in 10 quarters since. 37 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.
- Citigroup held 35,481 shares of Grace Therapeutics worth $76.3K as of Q3 2026.
- Grace Therapeutics was a new Citigroup position in Q3 2026.
- Grace Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4561 holding.
- Citigroup first reported a position in Grace Therapeutics in Q1 2014 and has held it in 10 quarters since.
- 37 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.